​

Funding Round

Series B - Celsius Therapeutics

Series B - Celsius Therapeutics

Investment Firm

Overview

Celsius Therapeutics is a biotechnology company that develops precision medicines for cancer and autoimmune disease patients.

Announced Date

Mar 24, 2022

Funding Type

Series B

Highlights

N/A

Location

N/A

Social

N/A

Investor Lead

Casdin Capital

Casdin Capital

Casdin Capital is a debt and early_stage_venture and late_stage_venture and post_ipo and seed and venture firm.

Participant Investors

10

Investor Name
Participant InvestorAmgen Ventures
Participant InvestorCurie.Bio
Participant InvestorSection 32
Participant InvestorGoogle Ventures
Participant InvestorThird Rock Ventures

Round Details and Background

Celsius Therapeutics raised $83000000 on 2022-03-24 in Series B

Celsius Therapeutics is a biotechnology company that develops precision medicines for cancer and autoimmune disease patients.

Company Funding History

2

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
May 15, 2018
Series A - Celsius Therapeutics
5-65.0M
Mar 24, 2022
Series B - Celsius Therapeutics
12-83.0M

Recent Activity

There is no recent news or activity for this profile.